Umberto Pensato։ Left Ventricular Dysfunction and DOAC Benefit in ESUS
Umberto Pensato, Assistant Professor of Neurology at the Humanitas University, Research Collaborator at the University of Calgary, shared on X about a recent article by Richa Sharma et al., published in Stroke, adding:
”Super important ARCADIA post hoc!
LV dysfunction is a treatment effect modifier of DOACs for stroke prevention.
(ie DOAC benefits only in ESUS with LV dysfunction).”
Title: Apixaban and Recurrent Stroke Risk With Left Ventricular Dysfunction: A Secondary Analysis of the ARCADIA Trial
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David L. Tirschwell, Alexander E. Merkler, Fadi Nahab
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 26, 2026, 03:43Shazmah Shaikh: How Laser Atherectomy Helps Clear Blocked Arteries
-
Oct 26, 2026, 03:28Priya Prasad: Protecting Donors and Recipients Through Blood Safety
-
Oct 25, 2026, 19:55Giacomo Buso: LIPLEG Provides the Strongest Evidence to Date on Lipedema Treatment
-
Oct 25, 2026, 19:54Nicholas Lee: ASH Program Connects Trainees and Faculty With Mentors for Career Development
-
Oct 25, 2026, 19:53World Thrombosis Day Raises Blood Clot Awareness at Italian Airports
-
Oct 25, 2026, 19:49Tahsim Anwar: A Six-Year Analysis of Adverse Events in Therapeutic Apheresis
-
Oct 25, 2026, 19:37William Wallace: More than 1 in 3 People with Parkinson’s Were Low in B6
-
Oct 25, 2026, 19:36Andrés Felipe Escobar González: Individualized Treatment Strategies for HMB in BDUC
-
Oct 25, 2026, 19:34Christophe Nougier: Returning to Burundi for the WFH-Supported Twinning Project